146 related articles for article (PubMed ID: 3712391)
1. The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
Harmer D; Evans DA; Eze LC; Jolly M; Whibley EJ
J Med Genet; 1986 Apr; 23(2):155-6. PubMed ID: 3712391
[TBL] [Abstract][Full Text] [Related]
2. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
3. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.
Zysset T; Peretti E
Eur J Clin Pharmacol; 1986; 30(4):463-6. PubMed ID: 3743623
[TBL] [Abstract][Full Text] [Related]
4. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
[TBL] [Abstract][Full Text] [Related]
6. Possible optimization of sulphadimidine dosage for acetylator phenotyping.
Hombhanje F
Jpn J Pharmacol; 1991 Aug; 56(4):531-4. PubMed ID: 1744992
[TBL] [Abstract][Full Text] [Related]
7. Acetylator polymorphism in rheumatoid arthritis.
Ladero JM; Andres MP; Bañares A; Fernández B; Hernández C; Benítez J
Eur J Clin Pharmacol; 1993; 45(3):279-81. PubMed ID: 8276055
[TBL] [Abstract][Full Text] [Related]
8. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
9. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
[TBL] [Abstract][Full Text] [Related]
10. Acetylation.
Weber WW
Birth Defects Orig Artic Ser; 1990; 26(1):43-65. PubMed ID: 2224079
[TBL] [Abstract][Full Text] [Related]
11. Hepatic acetylator polymorphism in breast cancer patients.
Ladero JM; Fernández MJ; Palmeiro R; Muñoz JJ; Jara C; Lázaro C; Pérez-Manga G
Oncology; 1987; 44(6):341-4. PubMed ID: 3684174
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis].
Milejski P; Orzechowska-Juzwenko K; Pawlik J; Kamienowski J; Horoch E; Niewiński P; Hurkacz M
Neurol Neurochir Pol; 1996; 30(4):571-9. PubMed ID: 9045059
[TBL] [Abstract][Full Text] [Related]
13. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial.
Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
Clin Pharmacol Ther; 1994 Aug; 56(2):142-53. PubMed ID: 8062490
[TBL] [Abstract][Full Text] [Related]
14. Relationship between acetylator phenotype and intensity of the hypoglycaemic effect of a suplhonamide preparation in children with insulin-dependent diabetes.
Hadasová E; Brysová V; Utĕsený J; Macků M
Bratisl Lek Listy; 1991 Dec; 92(12):609-14. PubMed ID: 1806177
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
[TBL] [Abstract][Full Text] [Related]
16. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Brøsen K; Davidsen F; Gram LF
Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
[TBL] [Abstract][Full Text] [Related]
17. Sparteine oxidation polymorphism in Denmark.
Brøsen K; Otton SV; Gram LF
Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
[TBL] [Abstract][Full Text] [Related]
18. Acetylator phenotype in psoriasis.
Jiménez-Nieto LC; Ladero JM; Fernández-Gundín MJ; Robledo A
Dermatologica; 1989; 178(3):136-7. PubMed ID: 2721804
[TBL] [Abstract][Full Text] [Related]
19. The genetic polymorphism of sparteine metabolism.
Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
[TBL] [Abstract][Full Text] [Related]
20. N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
Gawrońska-Szklarz B; Górnik W; Pawlik A; Kunicki P; Wójcicki J; Sitkiewicz D; Sych Z
Eur J Clin Pharmacol; 1997; 51(6):431-5. PubMed ID: 9112055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
